Basel, Switzerland – January 2009 – Evolva SA, an international biotech company focused on the discovery and development of drugs based on genetic chemistry approaches, is pleased to announce that it has entered into an exclusive worldwide licensing agreement with the UK Company, Summit Corporation plc (“Summit”). The agreement covers EV-009–4400 (SMT 14400), a second generation imino sugar, which is being developed as potential treatments for infectious diseases associated with bio-terrorism.
